Group 1 - The cosmetics sector experienced a slight increase of 0.09% on January 19, with Jinsheng New Materials leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up by 0.29%, while the Shenzhen Component Index closed at 14294.05, up by 0.09% [1] - Jinsheng New Materials saw a closing price of 18.89, with a significant increase of 7.70%, and a trading volume of 87,600 shares, amounting to a transaction value of 167 million yuan [1] Group 2 - The cosmetics sector faced a net outflow of 50.88 million yuan from institutional investors, while retail investors saw a net inflow of 42.92 million yuan [2] - The trading data indicates that LaFang Family, with a closing price of 22.58, experienced a decline of 3.30%, with a trading volume of 70,600 shares and a transaction value of 161 million yuan [2] - The individual stock performance shows that Beitaini had a net inflow of 25.48 million yuan from institutional investors, but a net outflow of 39.58 million yuan from retail investors [3]

Investment Rating - Industry rating: Recommended [4] Core Insights - The retail sales of consumer goods in December 2025 showed a year-on-year increase of 0.9%, which was below the expected 1.5%. The total retail sales for the year 2025 increased by 3.7% year-on-year, with specific categories such as furniture, cultural office supplies, cosmetics, and gold and silver jewelry showing growth rates of 14.6%, 17.3%, 5.1%, and 12.8% respectively [1][2] - The real estate sector faced significant challenges, with new housing starts, completed areas, sales areas, and investment in residential development all declining year-on-year by 18.8%, 20.6%, 18.9%, and 36.5% respectively in December 2025 [2][3] Summary by Category Home Furnishing - The home furnishing industry is expected to stabilize due to dual support from policies and the economy. The real estate market is showing signs of gradual recovery, which is anticipated to improve the demand for home furnishings [2] - The implementation of trade-in subsidies for durable consumer goods starting in Q4 2024 is expected to significantly activate consumer demand for home furnishings [2] Cosmetics - The cosmetics industry is experiencing steady recovery, with retail sales reaching 465.3 billion yuan in 2025, a year-on-year increase of 5.1%. December sales alone were 38 billion yuan, reflecting an 8.8% year-on-year growth [3][6] - The demand for cosmetics is shifting towards quality, efficacy, and brand value, with consumers willing to pay a premium for high-end skincare and professional makeup products [3][6] Gold and Jewelry - The gold and jewelry sector saw retail sales of 373.6 billion yuan in 2025, a year-on-year increase of 12.8%. In December, sales were 32.8 billion yuan, with a 5.9% year-on-year growth [7] - Despite pressure on sales volumes due to rising gold prices, the increase in prices has positively impacted retail sales, indicating a potential for continued growth in the market [7] Investment Recommendations - For home furnishing, focus on leading companies with strong channel capabilities and diversified product lines, such as Oppein Home and Kuka Home. Also, consider companies like Sensun Holdings that are expected to benefit from the recovery in the North American real estate market [8] - In the cosmetics sector, pay attention to high-end brands with Eastern cultural characteristics, such as Mao Geping and Lin Qingxuan, as well as companies like Marubi and Dengkang Oral that show clear improvement trends [8] - In the gold and jewelry sector, companies with high brand premium capabilities and differentiated pricing models, such as Laopu Gold, are recommended due to the ongoing upward trend in gold prices [8]

下一步，江苏省特殊化妆品质量检验检测中心将持续发挥"技术规范协同者""产学研转化枢纽"和"检测 认证服务者"三重角色，努力打造具有省内引领力和行业影响力的特殊化妆品技术服务平台，为江苏特 殊化妆品产业高质量发展提供坚实的技术支撑与服务保障，更好助力"美丽经济"高质量发展。 校对 陶善工 近日，由无锡市检验检测认证研究院筹建的江苏省特殊化妆品质量检验检测中心获批成立，标志着无锡 在特殊化妆品检验检测综合服务能力迈上新台阶，为全省乃至长三角地区特殊化妆品产业高质量发展提 供强有力的技术支撑。 江苏省特殊化妆品质量检验检测中心自获批筹建以来，不断推进实验场地建设，建成运行化妆品理化成 分分析、微生物检测、人体安全和功效评价以及动物替代试验等多个检测平台，检测范围涵盖了化妆品 的理化指标、微生物、禁限用物质等多个方面，能够满足不同类型化妆品的检测需求。能为企业提供包 括产品上市前合规与注册备案支持、型式检验/全项目检验、备案检测、监督抽检、风险物质筛查与监 测、产品研发与原料验证服务、配方协助开发、产品性能优化测试、原料和产品的功效验证、成分标注 符合性审核、法规咨询与标准服务、产品宣传设计等服务项目。中心"皮肤芯片 ...

成分之争在某种意义上是企业营销之争，系单一成分概念营销 引发的侧面影响。 作者：叶心冉 封图：图虫创意 过去一段时间，有关化妆品成分含量的争端频繁出现。2025年，上美集团旗下韩束、巨子生物旗 下可复美均因产品成分含量检测引发争议。 不同检测机构出具的结论不一：有的第三方检测结果显示某成分含量未达宣称标准，而品牌方拿出 的监管部门或其他权威机构的核验报告，却证实产品成分含量符合标识标注。 "公说公有理、婆说婆有理"的争论，让消费者的判断与信任陷入无所适从的困境。 但精准性并非不可实现，只要依托标准化检测方法、配备高灵敏度仪器、建立严格的质控流程（如 空白对照、加标回收、能力验证），同时提升机构专业度，就能在复杂基质中实现精准测量。 多数结果争议的核心，往往是部分机构采用非适宜方法、操作不规范导致的，而非技术上无法达成 精准。 经济观察报 ：目前，肽类、蛋白类等活性成分在化妆品领域的应用日益广泛，部分成分甚至成为 相关企业的核心竞争力。在此背景下，活性成分的精准检测面临哪些难点？ 从科学论证的角度，我们是不是根本无法获得成分含量的精确性检测结果？而对于化妆品功效而 言，成分差几克或者差几毫克，是否会产生截然不同 ...

Core Viewpoint - The ongoing disputes regarding cosmetic ingredient content highlight the complexities of ingredient testing and the challenges consumers face in discerning accurate information [1][2][3] Group 1: Disputes and Testing Challenges - Different testing institutions yield varying results for the same cosmetic ingredient, leading to consumer confusion and mistrust [2][4] - The complexity of cosmetic formulations, which often contain numerous ingredients, complicates the accuracy of testing results [4][5] - The lack of standardized testing methods contributes to discrepancies in results, as different institutions may use varying techniques and protocols [4][5][6] Group 2: Consumer Guidance and Industry Practices - Consumers are advised to prioritize testing institutions with recognized qualifications, such as CMA and CNAS, and to be cautious of unqualified third-party tests [7] - The impact of ingredient content variations can be significant, especially for active ingredients present in low concentrations, where small differences can affect efficacy [8][9] - The rise of ingredient-focused consumers has prompted brands to disclose more product information, making testing results a critical factor in product valuation [9][10] Group 3: Industry Development and Recommendations - The cosmetic industry is encouraged to adopt a foundation based on skin science and evidence-based practices to address the ongoing disputes and improve consumer communication [11][12][13] - Establishing a unified standard for ingredient testing that incorporates evidence-based data and involves diverse stakeholders is essential for enhancing credibility [12][13] - The industry must shift focus from mere ingredient content to the actual effects of ingredients on skin, ensuring that product efficacy and safety are prioritized [13]

中泰建交50载的暖光里，大马士革玫瑰的芬芳成了无界的语言。泰国查猜亲王与王妃的成都之行，开启 了一场以美为桥、以匠心为契的跨国相遇，为玫莉蔻的13年深耕写下温润注脚，让东方玫瑰护肤的温 度，被世界温柔看见。 两场相遇，一宴一园，看似偶然，实则必然。这份跨越山海的认可，从来不是偶然的幸运，而是玫莉蔻 13年深耕玫瑰护肤的必然结果——是对自然的虔诚敬畏，是对工艺的执着，是让护肤成为愉悦体验的初 心坚守。它无关商业的喧嚣，只关乎品质的纯粹与文化的共鸣，源于彼此的真诚与懂得。 园访初心：匠心的切身体验 次日清晨，亲王与王妃如约走进玫莉蔻玫瑰庄园概念旗舰店。没有繁复的接待流程，只有如同老友介绍 自家小院的坦诚分享，每一处空间都在诉说"一玫一心"的匠心故事。原料展示区里，从甄选的玫瑰原材 到特定的萃取工艺，从无数次配方调试到"自然+科技"的理念，每一个细节都在诉说"产品为何不同"的 答案。亲王一行专注聆听，时而颔首赞许，这份对精益求精的认可，无关国籍，只源于对美好事物的共 同执着。产品体验区里，亲王王妃再次邂逅"发光肌"，亲身体验后直言"欣赏这份健康通透的光泽"；小 憩时分，清雅的玫瑰花茶、专属面部与手部护理，让远道而来 ...

Core Viewpoint - Lin Qingxuan (02657) has seen a significant stock price increase, reaching a new high of 96 HKD, reflecting strong market performance and investor interest in the high-end skincare segment [1] Company Overview - Lin Qingxuan is a high-end domestic skincare brand in China, focusing on anti-wrinkle and firming skincare products, known for its use of natural camellia ingredients [1] - According to Zhi Shi Consulting, Lin Qingxuan ranks first among all high-end domestic skincare brands in China by retail sales, holding a 1.4% market share, and is the only domestic brand in the top 15 high-end skincare brands, which includes both domestic and international brands [1] Market Position and Growth Potential - Guotai Junan Securities reports that the company is well-positioned in the high-end skincare market and has entered a growth phase, particularly in the oil-based skincare segment, with expectations for continued high growth driven by flagship products and expansion on platforms like Douyin and offline channels [1] - Dongwu Securities suggests that Lin Qingxuan is in a growth phase characterized by brand momentum and channel benefits, recommending investors to pay close attention to the company [1]

Investment Rating - The report assigns an "Accumulate" rating to the company [6][11]. Core Viewpoints - The company has established itself in the high-end skincare market, pioneering the oil-based skincare segment. It is expected to experience rapid growth driven by its flagship products and ongoing expansion in both online and offline channels [2][11]. Financial Summary - The company is projected to achieve total revenue of RMB 805 million in 2023, increasing to RMB 4.274 billion by 2027, reflecting a compound annual growth rate (CAGR) of 27.3% [4]. - Net profit is expected to grow from RMB 85 million in 2023 to RMB 767 million by 2027, with a significant increase of 121.1% in 2024 [4]. - The company’s price-to-earnings (PE) ratio is projected to decrease from 27.93 in 2025 to 13.98 in 2027, indicating improving valuation metrics [4]. Company Overview - The company has been deeply involved in the oil-based skincare segment for many years, showcasing strong growth and profitability. It was founded in 2003 and has evolved its product offerings to focus on high-end anti-aging solutions [23][11]. - The flagship product, Camellia Oil, has been a market leader in the facial oil category for 11 consecutive years, demonstrating its effectiveness and market acceptance [11][23]. Industry Insights - The oil-based skincare segment is experiencing high demand, with the market for facial oils expected to reach RMB 5.3 billion in 2024, growing at a rate of 43% year-on-year [45][48]. - The overall anti-aging skincare market is projected to reach RMB 119.9 billion in 2024, with a growth rate of 11% [45][46]. Growth Drivers - The company is leveraging social media platforms like Douyin to drive sales of its flagship products, with online revenue expected to grow significantly [11][35]. - The expansion of offline retail channels is also anticipated to contribute to revenue growth, with over 554 stores established by mid-2025 [11][35].

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The lotion and cream categories are fundamental in skincare, primarily used for moisturizing and nourishing the skin, with distinctions based on texture, oil content, and suitable skin types/seasons [7] - Moisturizing remains the core demand with a 31% share, but its growth rate is stable at 5%, indicating a mature stage with limited growth potential. Nourishing creams, although only 5% of the market, show the highest growth rate at 16%, indicating a rising demand for high-nutrition lotions and creams [9][10] - The market is experiencing a shift, with a notable decline in demand for soothing, firming, and anti-wrinkle products, suggesting a saturation of these categories [9][10] Market Trends - The online sales landscape is shifting, with Douyin's sales share increasing from 44% to 49% and volume share from 47% to 67% between 2023 and 2025, while Tmall's shares are declining [16][22] - The average price on Tmall has risen significantly, while Douyin's average price dropped sharply, indicating a strategy focused on volume through lower pricing [15][20] - The overall market growth is slowing, with a projected sales growth of only 4.3% from 2024 to 2025, suggesting that companies need to adapt to channel characteristics [22] Competitive Landscape - The top brands on Tmall are dominated by high-end products, with significant sales figures, while Douyin shows a more fragmented market with rapid growth among new brands [24][26] - Domestic brands are leading in low-price, high-volume segments, while international brands maintain a high-price, low-volume strategy [26] - The report highlights the importance of product differentiation and the need for brands to focus on emerging trends and consumer demands to capture market share [11][12] Consumer Behavior - There is a significant demand for products targeting sensitive skin and repair, which are identified as "blue ocean" opportunities due to supply shortages [11] - The report indicates that high-demand, low-supply segments present opportunities for growth, while high-supply, low-demand segments require careful evaluation [12] Brand Strategies - Brands are increasingly leveraging live streaming and influencer partnerships to enhance visibility and sales, with a notable shift towards using influencers to reach broader audiences [50][57] - The report emphasizes the importance of maintaining a balance between high-end positioning and market penetration through various pricing strategies [41][42]

Core Viewpoint - The cosmetic industry faces its first IPO termination case in 2026, as Chuang'er Bio announces the cessation of its listing guidance due to unresolved shareholder equity freeze issues, marking its second failed IPO attempt [1][3][11]. Group 1: IPO Termination Reasons - The termination of the IPO guidance is attributed to the long-term unresolved issue of shareholder equity freeze, particularly involving the second-largest shareholder Ding Yumei, whose shares are frozen due to legal actions related to Evergrande's debt crisis [3][5][8]. - The company had previously attempted to go public, facing setbacks including two failed applications to the Sci-Tech Innovation Board and a subsequent shift to the Beijing Stock Exchange, which also did not yield results [10][11]. Group 2: Financial Performance and Challenges - Chuang'er Bio has struggled with fluctuating financial performance, with revenue consistently hovering between 240 million and 400 million RMB over the past six years, indicating a clear growth ceiling [12][14]. - The company's revenue for 2025 was reported at 214 million RMB for the first half, reflecting a year-on-year increase of 16.98%, but net profit plummeted by 55.99% to 13.21 million RMB, highlighting a trend of "increased revenue without increased profit" [13][14]. Group 3: Industry Context and Competitive Landscape - The collagen market is projected to surpass hyaluronic acid, becoming the leading ingredient in skincare by 2025, with a forecasted market size of 108.3 billion RMB by 2027, growing at a compound annual growth rate of 42.4% [16]. - Competitors like Juzhi Bio and Jinbo Bio have significantly outpaced Chuang'er Bio in both revenue and profitability, with Juzhi Bio's revenue soaring from 2.36 billion RMB in 2022 to 5.54 billion RMB in 2024, while Chuang'er Bio's growth remains stagnant [17][20]. Group 4: Regulatory and Technological Challenges - Regulatory tightening and the decline of the "medical device" business model have adversely affected Chuang'er Bio, which previously relied on its medical dressing products for competitive advantage [18]. - The shift in technology from animal-derived collagen to recombinant collagen has created a gap, with competitors advancing in this area while Chuang'er Bio remains focused on traditional collagen products [19][20]. Group 5: Future Outlook - The termination of the IPO is seen as a culmination of long-standing issues in industry competition, technological positioning, and capital utilization, suggesting that Chuang'er Bio must find a sustainable growth engine and differentiate itself in a competitive landscape to consider future IPO attempts [21].